Equity Overview
Price & Market Data
Price: $1.82
Daily Change: -$0.10 / 5.49%
Daily Range: $1.77 - $1.97
Market Cap: $358,740,192
Daily Volume: 5,221,659
Performance Metrics
1 Week: 27.46%
1 Month: 47.15%
3 Months: 107.8%
6 Months: -4.23%
1 Year: -14.22%
YTD: -17.73%
Company Details
Employees: 304
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.